MedTrace Logo

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

NCT00319618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2007-12-18

No results posted yet for this study

Summary

The purpose of this study is to determine if combination therapy of weekly Taxotere™ with Iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer

Conditions

Interventions

DRUG

Gefitinib

DRUG

Docetaxel

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Norway Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2006-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319618 on ClinicalTrials.gov